Apigenin analogues as SARS-CoV-2 main protease inhibitors: In-silico screening approach - Université Clermont Auvergne Accéder directement au contenu
Article Dans Une Revue Bioengineered Année : 2022

Apigenin analogues as SARS-CoV-2 main protease inhibitors: In-silico screening approach

Résumé

The COVID-19 new variants spread rapidly all over the world, and until now scientists strive to find virus-specific antivirals for its treatment. The main protease of SARS-CoV-2 (Mpro) exhibits high structural and sequence homology to main protease of SARS-CoV (93.23% sequence identity), and their sequence alignment indicated 12 mutated/variant residues. The sequence alignment of SARS-CoV-2 main protease led to identification of only one mutated/variant residue with no significant role in its enzymatic process. Therefore, Mpro was considered as a high-profile drug target in anti-SARS-CoV-2 drug discovery. Apigenin analogues to COVID-19 main protease binding were evaluated. The detailed interactions between the analogues of Apigenin and SARS-CoV-2 Mpro inhibitors were determined as hydrogen bonds, electronic bonds and hydrophobic interactions. The binding energies obtained from the molecular docking of Mpro with Boceprevir, Apigenin, Apigenin 7-glucoside-4’-p-coumarate, Apigenin 7-glucoside-4’-trans-caffeate and Apigenin 7-O-beta-d-glucoside (Cosmosiin) were found to be −6.6, −7.2, −8.8, −8.7 and −8.0 kcal/mol, respectively. Pharmacokinetic parameters and toxicological characteristics obtained by computational techniques and Virtual ADME studies of the Apigenin analogues confirmed that the Apigenin 7-glucoside-4’-p-coumarate is the best candidate for SARS-CoV-2 Mpro inhibition.
Fichier principal
Vignette du fichier
21655979.2022.pdf (3.03 Mo) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-03624323 , version 1 (30-03-2022)

Licence

Paternité

Identifiants

Citer

Ameny Farhat, Hajer Ben Hlima, Bassem Khemakhem, Youssef Ben Halima, Philippe Michaud, et al.. Apigenin analogues as SARS-CoV-2 main protease inhibitors: In-silico screening approach. Bioengineered, 2022, 13 (2), pp.3350--3361. ⟨10.1080/21655979.2022.2027181⟩. ⟨hal-03624323⟩
51 Consultations
91 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More